{"id":1641,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2017-06-28","marketCap":238.75259399414062,"name":"Mersana Therapeutics Inc","phone":"16174980020","outstanding":120.58000183105469,"symbol":"MRSN","website":"https://www.mersana.com/","industry":"Biotechnology"},"price":1.985,"year":2023,"month":12,"day":12,"weekday":"Tuesday","title":"Impact of Corporate Earnings Reports on Mersana Therapeutics Inc stock's price movements","date":"2023-12-12","url":"/posts/2023/12/12/MRSN","content":[{"section":"Q1 2021 Earnings Report","text":"Mersana Therapeutics Inc reported its Q1 2021 earnings on May 6, 2021. The company's revenue for the quarter was $1.2 million, compared to $0.4 million for the same period in the previous year. This significant increase in revenue was primarily due to collaboration and license agreement revenue recognized during the quarter. However, the company also reported a net loss of $18.7 million in Q1 2021, compared to a net loss of $11.2 million in Q1 2020. Following the earnings release, Mersana Therapeutics Inc's stock price experienced a decline of 5% on May 7, 2021."},{"section":"Q2 2021 Earnings Report","text":"On August 5, 2021, Mersana Therapeutics Inc announced its Q2 2021 earnings. The company reported total revenue of $0.9 million for the quarter, compared to $1.1 million in Q2 2020. The decrease in revenue was primarily attributed to the completion of a collaboration agreement in 2020. The net loss for the quarter was $10.6 million, compared to a net loss of $13.9 million in the same period last year. Despite the slightly improved financial performance, Mersana Therapeutics Inc's stock price experienced a decline of 7% on August 6, 2021, following the earnings release."},{"section":"Q3 2021 Earnings Report","text":"Mersana Therapeutics Inc's Q3 2021 earnings report was released on November 4, 2021. The company reported revenue of $0.7 million for the quarter, compared to $1.3 million in Q3 2020. The decrease in revenue was primarily due to the completion of a research collaboration in 2020. The net loss for the quarter was $8.9 million, compared to a net loss of $15.2 million in Q3 2020. Despite the improved financials and narrowing net loss, Mersana Therapeutics Inc's stock price experienced a decline of 10% on November 5, 2021, following the earnings release."},{"section":"Q4 2021 Earnings Report","text":"As of the time of this analysis, Mersana Therapeutics Inc has not announced its Q4 2021 earnings report."}],"tags":["CrossOver100","Long","Biotechnology"],"news":[{"category":"company","date":1701789541,"headline":"Citigroup Upgrades Mersana Therapeutics (MRSN)","id":124302854,"image":"","symbol":"MRSN","publisher":"Fintel","summary":"","url":"https://fintel.io/news/citigroup-upgrades-mersana-therapeutics-mrsn-983"},{"category":"company","date":1701749220,"headline":"GMAB, FNC and LOVE are among after hour movers","id":124332480,"image":"","symbol":"MRSN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242859565"},{"category":"company","date":1701687600,"headline":"What To Know About Citigroup's Upgrade of Mersana Therapeutics","id":124287706,"image":"","symbol":"MRSN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240671774"},{"category":"company","date":1701674100,"headline":"Mersana Therapeutics upgraded to Buy from Neutral at Citi","id":124287707,"image":"","symbol":"MRSN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240407237"},{"category":"company","date":1701466200,"headline":"Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","id":124244123,"image":"https://media.zenfs.com/en/globenewswire.com/141498d69b6404b72ac769e3f4d7fdc5","symbol":"MRSN","publisher":"Yahoo","summary":"CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on December 1, 2023, the Compensation Committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 12,205 shares of its common","url":"https://finance.yahoo.com/news/mersana-therapeutics-announces-inducement-grants-213000129.html"},{"category":"company","date":1701343620,"headline":"AbbVie-ImmunoGen buyout deal lifts ADC-focused biotechs","id":124204298,"image":"","symbol":"MRSN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3235302953"}]}